Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their ...

Recursion Pharmaceuticals (RXRX) closed the last trading session at $8.59, gaining 20% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set ...

Recursion Pharmaceuticals (RXRX Quick Quote RXRX - Free Report) shares soared 5.8% in the last trading session to close at $5.84. The move was backed by solid volume with far more shares changing ...

Two AI-driven disruptors, one biotech-focused, one software-first, post double-digit growth but diverge sharply on risk, cash flow, and valuation.